Cardinal Health 414 Company Profile
✉ Email this page to a colleague
What is the competitive landscape for CARDINAL HEALTH 414, and what generic alternatives to CARDINAL HEALTH 414 drugs are available?
CARDINAL HEALTH 414 has five approved drugs.
There are two US patents protecting CARDINAL HEALTH 414 drugs.
There are thirty patent family members on CARDINAL HEALTH 414 drugs in twelve countries and seventy-one supplementary protection certificates in nine countries.
Summary for Cardinal Health 414
| International Patents: | 30 |
| US Patents: | 2 |
| Tradenames: | 5 |
| Ingredients: | 5 |
| NDAs: | 5 |
Drugs and US Patents for Cardinal Health 414
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cardinal Health 414 | TECHNETIUM TC 99M SESTAMIBI | technetium tc-99m sestamibi kit | INJECTABLE;INJECTION | 078809-001 | Apr 28, 2009 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| Cardinal Health 414 | FLUDEOXYGLUCOSE F18 | fludeoxyglucose f-18 | INJECTABLE;INTRAVENOUS | 203603-001 | Nov 13, 2015 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ||||
| Cardinal Health 414 | LYMPHOSEEK KIT | technetium tc-99m tilmanocept | INJECTABLE;INJECTION | 202207-001 | Mar 13, 2013 | RX | Yes | Yes | 9,439,985 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Cardinal Health 414 Drugs
Supplementary Protection Certificates for Cardinal Health 414 Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1912999 | 1490062-5 | Sweden | ⤷ Sign Up | PRODUCT NAME: SIMEPREVIR, OR A SALT THEREOF, INCLUDING SIMEPREVIR SODIUM; REG. NO/DATE: EU/1/14/924 20140516 |
| 2932970 | 18C1043 | France | ⤷ Sign Up | PRODUCT NAME: UNE COMBINAISON COMPRENANT DU DOLUTEGRAVIR OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI,EN PARTICULIER LE SEL DE SODIUM DU DOLUTEGRAVIR,ET DE LA RILPIVIRINE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELLE-CI,EN PARTICULIER LE CHLORHYDRATE DE RILPIVIRINE; REGISTRATION NO/DATE: EU/1/18/1282 20180518 |
| 1666481 | 17C1031 | France | ⤷ Sign Up | PRODUCT NAME: TOFACITINIB,EVENTUELLEMENT SOUS LA FORME D'UN SEL PHARMACEUTIQUEMENT ACCEPTABLE,DONT LE CITRATE DE SODIUM; REGISTRATION NO/DATE: EU/1/17/1178 20170324 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
